Remission in cushing disease with cabergoline

Abstract

Risk factors, clinical feat t tures and outcome of acute myocardial infarct t tion in Sana´a, YemenTo the Editor: According to the World Health Organization, develo o oping countries contributed to 85% of cardiovasuclar disease (CVD) deaths. 1o3 A particular cause for concern is the relatively early age of CVD deaths compared with those in developed regions. Since there are few data on the incidence and clinical course of acute myocardial infarction (AMI) in the Middle East, 4o12 we retrospectively studied the demographic and clinical charo o acteristics of patients, the prevao o lence of major risk factors and faco o tors associated with morbidity and mortality during hospitalization in the intensive care unit (ICU) of the AloThawra University Hospital in Sana' a. All patients with confirmed AMI who were admitted and treato o ed at the intensive care unit (ICU) during 36 consecutive months were enrolled in the study. The diagnosis of AMI was based on a history of typical chest pain or its equivalent, ECG changes plus an increase in peak serum creatine kinase (CK) activity from a minimum to twice the normal level. During the 3oyear study period 386 patients with AMI were admitted to the ICU. Of all patients, 348 (90.2%) were men with a mean (±SD) age 54±11 years (range, 27o82 years) and 38 (9.8%) were women with a mean age of 59±11 years (range, 38o80 years). Almost all patients (97.9%) were Yemeni. The prevalence of risk factors was as follows: khat chewing (88%), smoking (81%), total serum cholesterol (29%), diabetes mellio o tus (25%) and hypertension (18%). When classified according to site, recurrence and severity of AMI, in 57.0% there was an anterior infarco o tion, in 35.2% an inferior infarction,

Remission with Cabergoline in Adolescent Boys with Cushing’s Disease

“…An extensive literature search revealed only a few reports of adolescent patients who were treated with cabergoline because of persistent CD after surgery and radiotherapy (9,16). Cabergoline treatment in childhood was reported by Gopal et al (9). Their patient was a 12-year-old boy who had persistent CD and who had undergone surgery and radiotherapy.…”

“…Medication treatment usually consists of use of adrenal-blocking drugs and neuromodulatory drugs acting at the pituitary level (8,9). However, inhibitors of steroidogenesis and the adrenolytic agent mitotane have limited efficacy or cause side effects that restrain their long-term utilization (5).…”